1. Home
  2. BNR vs NYXH Comparison

BNR vs NYXH Comparison

Compare BNR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$35.50

Market Cap

216.9M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$4.85

Market Cap

188.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
NYXH
Founded
2014
2009
Country
China
Belgium
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
216.9M
188.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
BNR
NYXH
Price
$35.50
$4.85
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$12.67
AVG Volume (30 Days)
34.1K
50.6K
Earning Date
11-20-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,749,382.00
$6,616,215.00
Revenue This Year
$136.32
$75.27
Revenue Next Year
N/A
$277.15
P/E Ratio
N/A
N/A
Revenue Growth
5.56
10.96
52 Week Low
$2.18
$4.35
52 Week High
$41.72
$11.87

Technical Indicators

Market Signals
Indicator
BNR
NYXH
Relative Strength Index (RSI) 66.47 49.67
Support Level $35.00 $4.70
Resistance Level $41.72 $5.00
Average True Range (ATR) 3.51 0.22
MACD 0.75 -0.02
Stochastic Oscillator 76.55 26.71

Price Performance

Historical Comparison
BNR
NYXH

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: